BA3021-001

Research code: BA3021-001
Research name: Phase I/II clinical trial with dose escalation and dose expansion stage with enrollment of additional patients for the selected dose of ozuriftamab vedotin (BA3021) as monotherapy and in combination with nivolumab in the treatment of patients with advanced solid tumors.
Indication: melanoma
Principal researcher: Ewa Chmielowska, MD, PhD